BACKGROUND: Assessment of left ventricular systolic function is necessary during
trastuzumab-based chemotherapy because of potential cardiotoxicity. Deformation indices …

Background Breast cancer (BC) survivors experience an increased burden of long-term
comorbidities, including heart failure (HF). However, there is limited understanding of the …

Background Epirubicin is a cytotoxic drug, widely used in patients with breast cancer, but its
application is limited by its cardiotoxicity. Assessment of left ventricular (LV) ejection fraction …

Importance Trastuzumab is a life-saving therapy but is associated with symptomatic and
asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic …

Background Anthracyclines and trastuzumab are well recognised to cause cardiac toxicity.
Further to their effects on left ventricular (LV) function, anthracyclines in particular are …

Background As cancer therapies have improved, patient life spans have been extended but
quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac …

Background More than 80% of breast cancer patients receive radiotherapy (RT). However,
RT can lead to cardiotoxicity, which usually develops insidiously over years, making …

Background Our objectives were to evaluate the temporal changes in CMR-based strain
imaging, and examine their relationship with left ventricular ejection fraction (LVEF), in …

Aims The benefits from anthracycline chemotherapy are undermined by potentially life-
threatening cardiotoxicity. Transthoracic echocardiography is the most commonly used …

Purpose: It is well known that anticancer drugs used for treating breast cancer can cause
cardiac toxicity, and less is known about vascular toxicity. The aim of this study was to …